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Pöllänen Petra M. et al 
Context: Characterization of slow progression to type 1 diabetes (T1D) may reveal novel means 
for prevention of T1D. Slow progressors might carry natural immunomodulators that delay β-cell 
destruction and mediate preservation of β-cell function. 
Objective: To identify demographic, genetic, and immunological characteristics of slow 
progression from seroconversion to clinical T1D. 
Design: HLA-susceptible children (n=7410) were observed from birth for islet cell (ICA), 
insulin (IAA), GAD65 (GADA), and islet antigen-2 autoantibodies (IA-2A), and for clinical T1D. 
Disease progression that lasted ≥7.26 years (slowest tertile) from initial seroconversion to 
diagnosis was considered slow. Autoantibody and genetic characteristics including 45 non-HLA 
single nucleotide polymorphisms (SNPs) predisposing to T1D were analyzed. 
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Results: By the end of 2015, altogether 1528 children (21%) had tested autoantibody positive, 
and 247 (16%) had progressed to T1D. The median delay from seroconversion to diagnosis was 
8.7 years in slow (n=62, 25%) and 3.0 years in other progressors. Compared to other progressors, 
slow progressors were less often multipositive, had lower ICA and IAA titers, and lower 
frequency of IA-2A at seroconversion. Slow progressors were born more frequently in the fall, 
while other progressors were born more often in the spring. Compared to multipositive non-
progressors, slow progressors were younger, had higher ICA titers, and higher frequency of IAA 
and multiple autoantibodies at seroconversion. We found no differences in the distributions of 
non-HLA SNPs between progressors. 
Conclusions: We observed differences in autoantibody characteristics and the season of birth 
among progressors, but no characteristics present at seroconversion that were specifically 
predictive for slow progression. 
We set out to characterize slow progression from seroconversion to overt type 1 diabetes. We found 
differences in autoantibodies and the season of birth, but no features specific for slow progression. 
Introduction 
Before the onset of clinical type 1 diabetes (T1D), autoantibodies against multiple β-cell antigens 
appear into the circulation as the first detectable sign of disease activity (1). The preclinical 
autoantibody profiles together with genetic factors can be used in disease prediction (2–3). 
Observations on individuals with islet autoantibodies have shown that the duration of this 
subclinical period is highly individual (4). It is plausible that critically timed environmental 
triggers are necessary for the initiation of the autoimmune response against the β-cells, but that 
individual genetic, immunological, or environmental mechanisms may modify the rate of the 
disease progression. 
 We have previously characterized rapid progressors to type 1 diabetes and observed that 
such children were younger, had higher autoantibody titers and tested more frequently positive 
for multiple autoantibodies at the time of seroconversion (5). The current study aims at 
describing the demographic, genetic, and immunological characteristics of slow disease 
progression in HLA-predisposed children recruited from the general population. Identifying the 
factors decisive for the progression rate might reveal insights into the pathomechanisms of the 
disease, lead to the discovery of natural immunomodulators and protective mechanisms behind 
the preservation of β-cell function, and provide a rationale for future interventions aimed at 
preventing or delaying the onset of clinical T1D. 
Materials and Methods 
Study participants and their samples 
The Type 1 Diabetes Prediction and Prevention (DIPP) Study is a prospective birth cohort study 
carried out in three Finnish University Hospitals in Oulu, Tampere, and Turku. The aims of the 
study are to monitor the development of islet-specific autoimmunity in children with T1D-
associated HLA risk genotypes recruited from the general population, and to identify strategies 
to delay or prevent clinical T1D in individuals at risk (6). 
 In the DIPP Study, the major disease risk-associated HLA genotypes have been assessed 
from cord blood. Study participants with eligible HLA-DR/DQ genotypes have been invited to 
follow-up, including immunological assessment, from the age of 3 months (6). The study has 
been carried out according to the principles of the Declaration of Helsinki. The local ethics 
committees of the participating hospitals have approved the study protocol. The legal 
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representatives of the newborn infants have given written informed consents for participation in 
the DIPP study. 
 The immunological follow-up includes regular venous blood sampling at clinical visits, 
starting from 3 months of age and continuing every 3 to 6 months until the age of 12–24 months 
and thereafter every 6–12 months (7). Children developing autoantibodies are invited to 
subsequent follow-up visits every 3 months in all three study centers. 
 The current study cohort comprised 7410 children (52.6% boys) who had participated in 
the follow-up for at least one year or had progressed to diabetes before the age of one year by the 
end of 2003 (Figure 1, Table 1). No cases of neonatal diabetes were observed. Participants with 
confirmed autoantibody positivity before T1D diagnosis were included in the detailed 
autoantibody analyses. 
Genetic screening 
Genotyping for the T1D risk-associated HLA-DR/DQ haplotypes was performed on cord blood 
samples by using PCR amplification, followed by time-resolved fluorometry with lanthanide-
labeled sequence-specific oligonucleotide probes, as previously described (6,8). The eligible 
children carried either the high-risk HLA-DQB1*02/*03:02 genotype or moderate-risk associated 
HLA-DQB1*03:02/x genotypes (x ≠ DQB1*02, *03:01, or *06:02) (9,10). 
 Single nucleotide polymorphism (SNP) markers were analyzed from individuals testing 
positive for at least one biochemical autoantibody [autoantibodies to insulin (IAA), glutamic acid 
decarboxylase (GADA), and/or islet antigen 2 (IA-2A)] in addition to islet cell antibodies (ICA) 
and from their autoantibody negative controls (two controls per case) matched for sex, study 
center, and the closest birth date (11). SNP genotypes were analyzed by using the Sequenom 
platform (San Diego, California, USA; Genome Center of Eastern Finland, University of Eastern 
Finland, Kuopio, Finland). Genotyping was considered successful if the failure rate remained 
under 10% (12). 
 Single nucleotide polymorphisms of non-HLA genes predisposing to T1D were selected 
for analysis by using a web-based resource comprising information on the genetics and the 
genomics of immune-mediated diseases in man (www.immunobase.org, formerly 
t1database.org). Regarding the current study cohort, data were available for 45 non-HLA SNPs 
predisposing to T1D (13–22). The associations of the predisposing SNPs with age at 
seroconversion, age at diagnosis of T1D, time from single to multiple autoantibody positivity, 
delay from seroconversion to diagnosis among progressors, and disease-free time after 
seroconversion in all participants with confirmed seropositivity were analyzed. 
Assessment of diabetes-associated autoantibodies 
The analyses of diabetes-associated autoantibodies were performed in the Research Laboratory, 
Department of Pediatrics, University of Oulu (Oulu, Finland). In the DIPP Study, the primary 
screening for β-cell autoimmunity was based on ICA from 1994 to 2003. The biochemical 
autoantibodies IAA, GADA, and IA-2A were analyzed from each child developing ICA 
positivity and/or T1D. All samples from all new participants have been analyzed for ICA and 
biochemical autoantibodies since 2003 and from the first one thousand children participating in 
the follow-up (from November 1994 to July 1997). For this study cohort, no data were available 
on zinc transporter 8 autoantibodies. 
 The analysis of ICA was performed using a standardized indirect immunofluorescence 
staining method, as previously described (23). The specific radiobinding assays used for the 
analysis of biochemical autoantibodies have been described in our earlier reports (7,24–26). 
According to the results from Diabetes Autoantibody Standardization Program (DASP) and the 
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Islet Autoantibody Standardization Program (IASP) in 2010–2015, the disease sensitivities of the 
IAA, GADA, and IA-2A radiobinding assays have been 36–62%, 64–88%, and 62–72%, 
respectively, while the corresponding disease specificities have been 94–98%, 94–99%, and 93–
100%, respectively. 
Definitions 
The date of draw for the first autoantibody-positive sample was defined as the date of 
seroconversion to autoantibody positivity. Confirmed autoantibody positivity was defined as 
positivity for at least one autoantibody in at least two consecutive samples. If the child had 
initially only one positive sample, but later on tested autoantibody positive in at least two 
consecutive samples, the date of the first positive sample was defined as the date of 
seroconversion. Simultaneous positivity for two or more autoantibodies in the same sample was 
considered as multipositivity. Inverse seroconversions, i.e. disappearances of autoantibodies 
were not considered. Type 1 diabetes was diagnosed according to the WHO criteria (27). 
 Progression to T1D was considered slow in cases where the disease-free period from 
seroconversion to the diagnosis of T1D lasted for at least 7.26 years. The cut-off was set at the 
75th percentile value of the delay from seroconversion to diagnosis among progressors. Although 
we have no biological evidence to support the selected cut-off (Figure 2), this definition provides 
a setting that enables us to investigate factors associated with a significantly longer delay from 
seroconversion to diagnosis than observed in the majority of the progressors in the DIPP Study 
cohort. In the whole study cohort, the median duration of prediabetic phase is 4.0 years. The 
multipositive non-progressors were defined as individuals with multiple autoantibodies, who 
remained unaffected by T1D by the end of 2015, and had been followed up for at least 7.26 years 
after seroconversion to autoantibody positivity. 
Data management and statistical analyses 
IBM SPSS predictive analytics software for Macintosh (version 25.0, Armonk, NY, USA) was 
used for multiple parametric and non-parametric statistical analyses. The confidence interval was 
set at 95% and the statistical significance at P<0.05 (two-sided). Cross-tabulation, the Pearson’s 
χ
2
 test, the Fisher’s exact test, the Mann-Whitney U test, and the Kruskall-Wallis test were used 
to test statistical differences between the study subgroups. Categorical variables were analyzed 
by using the Pearson’s χ2 test and the Fisher’s exact tests, when appropriate. Non-parametric 
variables were analyzed by using the Mann-Whitney U and the Kruskall-Wallis tests. While 
comparing autoantibody levels, only individuals who tested positive for the specific autoantibody 
reactivity were included in the analyses. In the SNP analyses, P values of the multiple 
comparisons were corrected for by applying the Benjamini-Hochberg step-up procedure using 
the cumulative minimum principle (R software for statistical computing for Macintosh 3.3.3) 
(28). 
Results 
Identifying study subgroups 
The current study cohort was observed from birth over a median follow-up time of 16.2 years 
(range 0.9–21.1 years). Among these children, 1528 (20.6%) had confirmed positivity for at least 
one T1D-associated autoantibody, and 247 (16.2%) of the children with confirmed autoantibody 
positivity progressed to T1D by the end of 2015 (Table 1). The median age at seroconversion 
was 5.0 years (Table 1). Regarding the children with autoantibodies, we focused on three 
subgroups: the slow progressors, other progressors, and non-progressors who developed multiple 
autoantibodies during the follow-up. The median delay from seroconversion to diagnosis was 8.7 
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years (range 7.3–17.0) in slow progressors (n=62, 25.1% of the progressors), and 3.0 years 
(range 0.02–7.2) in other progressors (n=185, 74.9%) (Table 2, Figure 2). 
Slow progressors vs. other progressors 
Compared to other progressors, the slow progressors had lower titers of ICA and IAA, and lower 
frequency of IA-2A and multipositivity at seroconversion (Table 2). Considering progressors 
who were positive for a single autoantibody at seroconversion, the delay from single to multiple 
autoantibody positivity was longer in slow progressors compared to other progressors (Table 2). 
Slow progressors tended to have been born more often in the fall (from September to November) 
compared to other progressors (31 vs. 22%), while other progressors were born more frequently 
in the spring (from March to May; 15 vs. 31%; p=0.04) (Figure 3). We observed no significant 
differences between the two groups in sex distribution, age at seroconversion, prevalence of the 
high-risk HLA-DQB1*02/*03:02 genotype, frequency of T1D-affected first-degree relatives at 
birth of the child, positivity for ICA, IAA, and GADA, or the titers of GADA and IA-2A at 
seroconversion (Table 2). 
Slow progressors vs. multiple autoantibody-positive non-progressors 
Since the majority of children with multiple autoantibodies develop clinical disease during 
childhood, the current multipositive non-progressors may still progress to T1D, although 
remarkably slowly (29). Thus, as expected, the two groups comprising slow progressors and 
multipositive non-progressors shared several common characteristics. However, there were also 
significant differences. Compared to the multipositive non-progressors, the slow progressors 
were younger, had higher titers of ICA, and higher frequencies of IAA and multiple 
autoantibodies at seroconversion (Table 2). The multipositive non-progressors tested more often 
GADA positive at seroconversion without simultaneous presence of IAA (Table 2). 
Autoantibody status at seroconversion 
As previously observed, the disease process beginning with IAA as the first detectable 
autoantibody shows a different pattern of β-cell autoimmunity compared to that beginning with 
GADA positivity (30). This phenomenon tended to hold true also in the current study cohort: 
most progressors (41.3%), both slow (45.2%) and the other progressors (40.0%), were IAA 
positive and GADA negative at seroconversion, and only 19.4% had GADA positivity without 
simultaneous IAA positivity at seroconversion (P=0.27). One third of the multipositive non-
progressors (27.8%) were GADA positive and IAA negative at seroconversion, compared to the 
frequencies of 14.5% and 21.1% among the slow and the other progressors, respectively (P=0.04 
compared to all progressors). Notably, 79.0% of all seroconverted non-progressors were single 
ICA positive at seroconversion (13). As expected, multipositive seroconversions were more 
common in slow (43.5%) and other progressors (63.2%) compared to seroconverted non-
progressors (5.5%; P<0.001). However, our primary focus was on identifying the factors 
predictive for the pace of the disease process present at seroconversion, and we did not consider 
the possible loss of observed autoantibody signatures during the follow-up. 
Non-HLA SNPs and progression rate  
As the SNP data in the current study cohort were originally generated for other purposes, the 
coverage of the SNP data set was not optimal considering comprehensive analyses in the whole 
cohort. To survey whether the previously described T1D predisposing SNPs might associate with 
progression rate, we investigated their association with the delay from seroconversion to 
diagnosis, and their distributions between the groups of slow progressors, other progressors, and 
multipositive non-progressors (Table 3; 13). Although several non-HLA SNPs associated with 
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the delay from seroconversion to diagnosis, after correction for multiple testing by using the 
Benjamini-Hochberg step-up procedure, the differences in the distributions turned out to be 
statistically non-significant. For T1D-associated SNPs, the main focus was to find SNPs 
associated with the pace of disease progression rather than overall progression to T1D. However, 
considering the maturation of immunity, we found interesting that the predisposing 
GPR183/EBI2 SNP seemed to associate with overall progression to T1D among all children 
tested in the study cohort, regardless of their autoantibody status (GPR183/EBI2 CC, CT 
genotype, progressors 51 vs. non-progressors 41%; P=0.008, Pc=0.06). Also, the predisposing 
PTPN22, INS (rs689), and PHTF1 SNPs associated with progression to T1D after correction for 
multiple comparisons (13). 
Discussion 
The progressive increase in the incidence rate of type 1 diabetes in most Western countries over 
the last decades emphasizes the need to generate innovative means for delaying or preventing 
T1D (31). Individuals with slow disease progression may possess protective mechanisms that 
postpone the transition from islet autoimmunity to clinical disease. Identifying such mechanisms 
might provide targets for immunomodulatory therapies aimed at slowing down the disease 
process. 
 In this prospective birth cohort study comprising 7410 children recruited from the general 
population based on HLA-conferred disease risk, we aimed at identifying individuals with slow 
progression to T1D. We observed differences in autoantibody characteristics and the season of 
birth among the progressors. However, no specific characteristics present at seroconversion 
predicted slow progression. The main challenge was to distinguish features related to slow 
progression from the ones predicting overall progression to T1D. 
 Compared to other progressors, the slow progressors tested less often positive for 
multiple autoantibodies and IA-2A, had lower titers of ICA and IAA at seroconversion, and 
progressed more slowly from single to multiple autoantibody positivity. We observed variation 
in the seasonality of birth among the progressors: slow progressors were often born in the fall, 
while other progressors were born more frequently in the spring. Compared to multiple 
autoantibody-positive non-progressors, slow progressors were younger, had higher ICA titers, 
and higher frequency of IAA and multiple autoantibodies at seroconversion. The multipositive 
non-progressors tested more often positive for GADA without the simultaneous presence of IAA 
at seroconversion. 
 The DAISY study reported that slow progressors had later onset of islet autoimmunity, 
were less likely to develop IAA positivity, had lower levels of autoantibodies, especially the 
initial levels of IAA, and progressed more slowly from single to multiple autoantibody positivity 
compared to rapid and moderate rate progressors (32). In the BABYDIAB study, later 
appearance of IA-2A positivity associated with slower disease progression, and some differences 
were reported in the distributions of non-HLA SNPs (33). A genetic risk score predicted 
progression rate of islet autoimmunity in the TEDDY cohort (34). Our results support previous 
observations, showing that lower initial levels of autoantibodies, including IAA, lower frequency 
of IA-2A positivity at seroconversion, and slower progression from single to multiple 
autoantibody positivity are characteristic of slow progression to clinical disease. Partly due to 
non-optimal data coverage and relatively small sample size, we found no differences between the 
progression groups in the distributions of the analyzed non-HLA alleles. 
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 Since the majority of the multipositive children will eventually develop clinical diabetes, 
it seems plausible that the current autoantibody-positive non-progressors who later on developed 
multiple autoantibodies may still progress to T1D, although extremely slowly (29). In fact, 
compared to both progressors and single autoantibody-positive non-progressors, multipositive 
non-progressors had a distinct autoantibody profile at seroconversion. This non-progression or 
ultraslow progression associated pattern of autoantibody positivity starts at an older age with 
GADA-positive signature. As previously observed, islet autoimmunity initiating with IAA 
positivity is associated with younger age at diagnosis and homozygosity for the HLA-DR4-DQ8 
genotype, whereas GADA as the first autoantibody is associated with older age and HLA-DR3-
DQ2 homozygosity (30). IAA as the first autoantibody peaks during the second year of life, 
while GADA reactivity tends to appear later, and with a considerably lower and broader peak 
(35–37). Individuals testing positive for multiple autoantibodies but remaining unaffected for 
≥10 years after the seroconversion are frequently GADA positive in their first sample positive 
for multiple autoantibodies (38). As the T1D-linked Coxsackievirus B1 infections have been 
associated with the appearance of IAA as the first autoantibody, but not with initial GADA 
positivity (39), the current observations support the idea that the triggers of the autoimmune 
process may be heterogeneous. Moreover, at least to some extent, the first autoantibody signature 
seems to predict the progression rate to clinical T1D. Comparisons between phenotypically 
variable progressors and multipositive non-progressors are valuable, since they may reveal 
protective mechanisms capable of slowing down the disease process. 
 Although no associations between the T1D-predisposing non-HLA SNPs and the pace of 
the disease progression were observed after correction for multiple testing, the finding that the 
predisposing GPR183/EBI2 SNP tended to associate with overall progression to T1D was 
notable. This gene encodes the G protein-coupled receptor 183, a chemokine receptor (Ebstein-
Barr virus-induced G protein-coupled receptor 2, EBI2), which regulates the migration of the 
immune cells in lymphoid tissues (reviewed in 40). Deficiencies in EBI2 or its ligand 7α,25-
dihydroxycholesterol lead to defective humoral immune responses and impaired thymic 
negative selection in mice, and may affect central tolerance by controlling the migration rate of 
medullary thymocytes (40–41). EBI2-associated B cell responses may well be involved in the 
heterogeneity of the T1D pathogenesis, since in recent-onset T1D patients, two distinct profiles 
of insulitis (characterized by high vs. low frequencies of CD20-positive B cells) have been 
associated with significantly different age at diagnosis (42). 
 The variation observed in the seasonality of birth among the progressors implies that 
seasonal environmental factors, such as infections or nutritional factors, may play a role in the 
initiation of the β-cell autoimmunity, and in the determination of the progression rate to clinical 
disease. It has been suggested that early encounters with seasonal pathogens, especially with 
viruses, might trigger β-cell autoimmunity as early as in utero or in the perinatal period (43). Not 
surprisingly, certain enteroviruses that have been consistently associated with the initiation of the 
β-cell autoimmunity are among the strongest candidates for seasonal disease-associated 
pathogens (reviewed in 44). Considering that enteroviral infections peak in the late summer or 
early fall in Finland, the seasonality of birth observed among slow and other progressors 
suggests that enteroviral antigen presentation in the late pregnancy or early neonatal period may, 
in fact, slow down the disease process (National Infectious Diseases Register, National Institute 
for Health and Welfare, Finland). This might be explained by the fact that infants born in the 
spring may be exposed to such antigens at an older age when the protection of the maternal 
antibodies has vanished. In the DIPP study, the Coxsackievirus B1 infection-associated risk of 
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islet autoimmunity has been observed to be reduced in the presence of maternal anti-viral 
antibodies (45). The seasonality of birth in T1D patients has been reported in several 
populations, but the observations are inconsistent, probably reflecting the variations in the 
incidence of T1D, in the genetic background, in lifestyle, and in endemic seasonal pathogens of 
different populations (46). 
 In conclusion, we observed differences in autoantibody characteristics and seasonality of 
birth in relation to the progression rate to overt T1D. However, we found no specific 
characteristics present at seroconversion unambiguously predictive for slow progression. As 
slow progressors may represent individuals that possess protective mechanisms slowing down 
the progression to clinical disease, further investigations on the genetic, immunological, and 
environmental factors modifying the rate of disease progression are needed. They might provide 
insights into the pathomechanisms of T1D and reveal novel targets for future preventive 
interventions. 
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Figure 3 Season of birth in slow and other progressors.  *Slow vs. other progressors. **Slow 
progressors vs. multipositive non-progressors, Other progressors vs. multipositive non-
progressors 
Table 1 Background variables and data on islet autoimmunity in the current study cohort 
(NAll=7410). JDFU=Juvenile Diabetes Foundation units, RU=Relative units. 
 N (%) 
Sex  
Boys 3895 (52.6) 
HLA genotype  
High-risk HLA genotype DQB1*02/*0302 1575 (21.3) 
Moderate-risk HLA genotypes DQB1*0302/x a 5835 (78.7) 
First-degree relatives affected by type 1 diabetes 177 (2.4) 
Seroconversion to autoantibody positivity  
≥1 positive autoantibodies in ≥2 consecutive samples 1528 (20.6) 
ICA 1214 (16.4) 
IAA 301 (4.1) 
GADA 257 (3.5) 
IA-2A 83 (1.1) 
Multipositivity at seroconversion 214 (2.9) 
Multipositivity in subsequent samples 272 (3.7) 
Progression to clinical type 1 diabetes  
During the follow-up 247 (16.2) 
Disease-free for ≥ 7.26 years from seroconversion 62 (25.1% of the progressors) 
 Median (range) 
Follow-up time, years 16.2 (0.9–21.1) 
Delay from seroconversion to diagnosis, years 4.0 (0.02–17.0) 
Age at seroconversion, years 5.0 (0.2–15.1) 
Age at diagnosis, years 7.6 (0.9–18.0) 
Time from single to multiple autoantibody positivity, years 1.0 (0.2–10.5) 
Autoantibody titers at seroconversion  
ICA, JDFU (n=1214) 5 (2.5–668) 
IAA, RU (n=301) 7.9 (3.5–148.7) 
GADA, RU (n=262) 19.5 (5.4–342.1) 
IA-2A, RU (n=84) 13.0 (0.4–121.0) 
a 
x ≠ DQB1*02, *03:01, *06:02 
Table 2 Clinical characteristics for the slow progressors, other progressors, and multiple 
autoantibody positive non-progressors. 
aSlow progressors vs. other progressors 
bSlow progressors vs. multiple autoantibody-positive non-progressors 
cOther progressors vs. multiple autoantibody-positive non-progressors 
 PROGRESSORS  NON-PROGRESSORS  
 Slow progressors (n=62)
Other progressors 
(n=185) P
a
 
Multipositive non-progressors 
(n=198) P
b
 P
c
 
 N (%)      
HLA genotype       
High risk HLA genotype 24 (39) 78 (42) 0.63 57 (29) 0.14 0.006
Sex       
Boys 35 (57) 107 (58) 0.85 123 (62) 0.43 0.39 
Affected first-degree relatives 4 (7) 24 (13) 0.16 14 (7) 1.00 0.054
AAB positivity at seroconversion,        
ICA 30 (48) 112 (61) 0.09 110 (56) 0.32 0.32 
IAA 44 (71) 126 (68) 0.67 68 (34) <0.001<0.001
GADA 25 (40) 91 (49) 0.23 71 (36) 0.53 0.008
IA-2A 5 (8) 50 (27) 0.002 18 (9) 0.80 <0.001
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IAA positive without GADA 28 (45) 74 (40) 0.48 52 (26) 0.005 0.004
GADA positive without IAA 9 (15) 39 (21) 0.26 55 (28) 0.03 0.13 
IAA and GADA 16 (26) 52 (28) 0.73 16 (8) <0.001<0.001
Multipositivity 27 (44) 117 (63) 0.006 51 (26) 0.008 <0.001
Multiple biochemical autoantibodies 17 (27) 74 (40) 0.08 22 (11) 0.002 <0.001
Multipositivity during follow-up 62 (100) 182 (98) 0.31 198 (100)   
 Median (range)      
AAB levels at seroconversion       
ICA, JDFU 7 (4–131) 15 (3–668) 0.001 5 (3–110) 0.003 <0.001
IAA, RU 7.1 (3.5–40.3) 10.2 (3.6–81.0) 0.003 7.0 (3.5–148.7) 0.78 <0.001
GADA, RU 21.0 (5.9–135.3) 32.9 (5.6–310.4) 0.13 16.9 (5.5–342.1) 0.52 0.009
IA-2A, RU 9.8 (0.4–57.3) 22.9 (0.6–121.0) 0.20 2.7 (0.5–70.4) 0.88 0.003
Age at seroconversion, years 1.5 (0.6–7.5) 2.0 (0.3–13.8) 0.29 3.5 (0.2–13.1) <0.001<0.001
Age at diagnosis, years 11.4 (8.6–18.0) 5.5 (0.9–17.4)     
Delay from seroconversion to diagnosis, years 8.7 (7.3–17.0) 3.0 (0.02–7.2)     
Time from single to multiple autoantibody 
positivity, years 1.5 (0.2–8.2) 0.5 (0.2–6.0) 0.01 1.8 (0.2–10.5) 0.13 <0.001
Follow-up time from seroconversion, years 8.7 (7.3–17.0) 3.0 (0.02–7.2)  12.8 (7.4–20.1)   
Table 3 Predisposing SNPs associated with the delay from seroconversion to diagnosis of type 1 
diabetes in progressors. NS=non-significant, Pc=corrected P value after the Benjamini-Hochberg 
corrections for multiple comparisons. 
Gene SNP Genotype (n) Median (range) P value Pc
 
RGS1 rs2816316 TT (148) 4.6 (0.02–17.0) 0.03 NS 
  GT, GG (55) 3.5 (0.12–11.8)   
FUT2 rs601338 AA, AG (133) 4.8 (0.1–17.0) 0.04 NS 
 GG (69) 3.1 (0.02–12.3)   
LOC646538 rs630115 GG (108) 4.6 (0.1–15.1) 0.01 NS 
 AA, AG (118) 3.4 (0.02–17.0)   
IGF2BP2 rs4402960 GT, GG (219) 4.3 (0.02–17.0) 0.04 NS 
 TT (18) 2.8 (0.2–7.6)   
High risk HLA genotype     
SH2B3 rs3184504 TT (12) 2.4 (0.1–11.0) 0.04 NS 
  CT, CC (75) 4.1 (0.1–12.0)   
CTSH rs3825932 TT (16) 2.3 (0.2–8.0) 0.01 NS 
  CT, CC (81) 4.1 (0.1–12.0)   
SLC30A8 rs13266634 TT (8) 7.5 (0.3–10.6) 0.04 NS 
  CT, CC (91) 3.5 (0.1–12.0)   
FUT2 rs601338 AA, AG (56) 4.7 (0.3–12.0) 0.02 NS 
  GG (31) 2.7 (0.1–11.4)   
Moderate risk HLA genotype     
ERBB3 rs2292239 AA (15) 2.4 (0.1–15.4) 0.007 NS 
  AC, CC (120) 4.7 (0.02–17.0)   
IL2RA rs11594656 TT, AT (112) 4.4 (0.1–17.0) 0.04 NS 
  AA (3) 1.2 (0.2–3.4)   
GIMAP5 rs6965571 GG (100) 5.1 (0.1–15.4) 0.03 NS 
  AG, AA (36) 2.6 (0.02–17.0)   
SLC30A8 rs13266634 CC, TT (76) 3.9 (0.1–15.4) 0.03 NS 
  CT (63) 5.7 (0.02–17.0)   
Boys      
LOC646538 rs630115 GG (61) 5.6 (0.3–15.1) 0.004 NS 
  AG, AA (68) 3.3 (0.1–17.0)   
IGF2BP2 rs4402960 GT, GG (126) 4.5 (0.1–17.0) 0.02 NS 
  TT (8) 2.7 (0.2–4.1)   
NRP1 rs2666236 AA, AG (76) 5.3 (0.1–17.0) 0.04 NS 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-01069/5532586 by Viikki Science Library, U
niversity of H
elsinki user on 30 July 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-01069 
 
 
15 
  GG (40) 3.1 (0.1–12.3)   
Girls      
KIAA0350-CLEC16A rs2903692 GG (35) 3.0 (0.1–10.6) 0.05 NS 
  AG, AA (49) 5.3 (0.02–11.4)   
AFF3 rs9653442 CC (16) 2.3 (0.1–8.0) 0.02 NS 
  CT, TT (71) 4.4 (0.02–11.8)   
INS rs689 TT (2) 9.3 (8.0–10.7) 0.04 NS 
  AA, AT (101) 3.6 (0.02–11.8)   
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